These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15573025)

  • 1. Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic-pituitary-adrenal axis and noradrenergic function.
    Coplan JD; Mathew SJ; Smith EL; Trost RC; Scharf BA; Martinez J; Gorman JM; Monn JA; Schoepp DD; Rosenblum LA
    CNS Spectr; 2001 Jul; 6(7):607-12, 617. PubMed ID: 15573025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine.
    Stine SM; Grillon CG; Morgan CA; Kosten TR; Charney DS; Krystal JH
    Psychopharmacology (Berl); 2001 Mar; 154(3):274-81. PubMed ID: 11351934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects.
    Krystal JH; Webb E; Cooney NL; Kranzler HR; Southwick SW; Heninger GR; Charney DS
    Am J Psychiatry; 1996 Jan; 153(1):83-92. PubMed ID: 8540598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha 2-adrenergic receptor function in depression. The cortisol response to yohimbine.
    Price LH; Charney DS; Rubin AL; Heninger GR
    Arch Gen Psychiatry; 1986 Sep; 43(9):849-58. PubMed ID: 3019271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noradrenergic response to acute ethanol administration in healthy subjects: comparison with intravenous yohimbine.
    McDougle CJ; Krystal JH; Price LH; Heninger GR; Charney DS
    Psychopharmacology (Berl); 1995 Mar; 118(2):127-35. PubMed ID: 7617798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients.
    Stine SM; Southwick SM; Petrakis IL; Kosten TR; Charney DS; Krystal JH
    Biol Psychiatry; 2002 Apr; 51(8):642-51. PubMed ID: 11955464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha2-adrenoceptor regulation of the hypothalamic-pituitary-adrenocortical axis in obesity.
    Pasquali R; Vicennati V; Calzoni F; Gnudi U; Gambineri A; Ceroni L; Cortelli P; Menozzi R; Sinisi R; Rio GD
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):413-21. PubMed ID: 10762283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncoupling of the noradrenergic-hypothalamic-pituitary-adrenal axis in panic disorder patients.
    Coplan JD; Pine D; Papp L; Martinez J; Cooper T; Rosenblum LA; Gorman JM
    Neuropsychopharmacology; 1995 Aug; 13(1):65-73. PubMed ID: 8526972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
    Krystal JH; Abi-Saab W; Perry E; D'Souza DC; Liu N; Gueorguieva R; McDougall L; Hunsberger T; Belger A; Levine L; Breier A
    Psychopharmacology (Berl); 2005 Apr; 179(1):303-9. PubMed ID: 15309376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone.
    Vythilingam M; Anderson GM; Owens MJ; Halaszynski TM; Bremner JD; Carpenter LL; Heninger GR; Nemeroff CB; Charney DS
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4138-45. PubMed ID: 11095445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noradrenergic dysregulation during discontinuation of cocaine use in addicts.
    McDougle CJ; Black JE; Malison RT; Zimmermann RC; Kosten TR; Heninger GR; Price LH
    Arch Gen Psychiatry; 1994 Sep; 51(9):713-9. PubMed ID: 8080348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of yohimbine in obsessive compulsive disorder.
    Rasmussen SA; Goodman WK; Woods SW; Heninger GR; Charney DS
    Psychopharmacology (Berl); 1987; 93(3):308-13. PubMed ID: 2829264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma MHPG response to yohimbine treatment in women with hypoactive sexual desire.
    Piletz JE; Segraves KB; Feng YZ; Maguire E; Dunger B; Halaris A
    J Sex Marital Ther; 1998; 24(1):43-54. PubMed ID: 9509380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
    Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
    Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine.
    Charney DS; Breier A; Jatlow PI; Heninger GR
    Psychopharmacology (Berl); 1986; 88(2):133-40. PubMed ID: 3081923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Acute Confinement Stress-induced Hypothalamic-Pituitary Adrenal Axis Activation and Concomitant Peripheral and Central Transforming Growth Factor-β1 Measures in Nonhuman Primates.
    Coplan JD; Gopinath S; Abdallah CG; Margolis J; Chen W; Scharf BA; Rosenblum LA; Batuman OA; Smith EL
    Chronic Stress (Thousand Oaks); 2017 Feb; 1():. PubMed ID: 28393139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the naloxone test with ovine CRH and insulin hypoglycaemia in the evaluation of the hypothalamic-pituitary-adrenal axis in normal man.
    Inder WJ; Ellis MJ; Evans MJ; Donald RA
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):425-31. PubMed ID: 7586616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further characterization of brain 3,4-dihydroxyphenylethyleneglycol (DHPG) formation: dependence on noradrenergic activity and site of formation.
    Li PP; Warsh JJ; Godse DD
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Jan; 332(1):26-33. PubMed ID: 3951564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740.
    Procaccini C; Maksimovic M; Aitta-Aho T; Korpi ER; Linden AM
    Neuroscience; 2013 Oct; 250():189-200. PubMed ID: 23867766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.